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of respiratory symptoms. All antineoplas-
tic drugs were discontinued. With predni-
sone 50 mg daily, tapered off over 6 weeks, 
symptoms resolved promptly, and lung 
function tests and CT scan after 6 weeks 
documented improvement ( table 1 ). We 
assumed bevacizumab more likely caus-
ative for drug-induced pneumonitis than 
PLD as there are much more safety data 
available for PLD without clear evidence of 
interstitial pneumonitis related to PLD  [1] . 
Thus, we decided to reinitiate PLD alone 
after a 3-month treatment holiday. No pul-
monary side effects were noted, suggesting 
bevacizumab being the cause of interstitial 
pneumonitis. Pulmonary complications 
observed so far with bevacizumab are 
hemorrhage and hemoptysis, mainly ob-
served in lung cancer patients and more 
commonly seen in patients with squamous 
cell carcinoma of the lung than in those 
with nonsquamous histology  [2] . Only 
lately, a first description of interstitial 
pneumonitis in a patient treated with the 
combination of bevacizumab and docetax-
el has been reported  [3] .
 The pathogenesis of antineoplastic 
drug-induced lung injury is poorly under-
stood. Direct injury to pneumocytes or the 
alveolar capillary endothelium (chemical 
 We report on a patient with metastatic 
breast cancer in whom interstitial pneu-
monitis developed after treatment with 
bevacizumab in combination with pe-
gylated liposomal doxorubicin (PLD). Re-
exposure to PLD after recovery was with-
out any pulmonary side effects.
 A 53-year-old woman presented with 
symptomatic histologically proven diffuse 
metastatic infiltration of the stomach as 
the only site of disease 5 years after pri-
mary diagnosis of lobular breast cancer. 
Treatment with PLD (Caelyx  ) 20 mg/
m 2 in combination with bevacizumab 
(Avastin  ) 10 mg/kg every 2 weeks was 
started in a study protocol.
 Treatment was initially well tolerated 
and abdominal symptoms disappeared 
completely. After 3 courses of treatment, 
the patient developed persistent cough and 
shortness of breath. High-resolution CT 
scan showed ground glass opacities com-
patible with interstitial pneumonitis. 
Analysis of arterial blood gases confirmed 
the presence of hypoxemia. As history and 
diagnostic work-up could rule out other 
causes of interstitial pneumonitis (infec-
tions, tumor progression and autoimmune 
disorders), drug-induced interstitial pneu-
monitis was regarded the most likely cause 
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alveolitis) may contribute to chemothera-
py-induced lung injury. Monoclonal anti-
bodies like rituximab and trastuzumab 
have also been associated with interstitial 
pneumonitis. Cytokine release and inabil-
ity of pneumocytes to respond to lung in-
jury through HER2 inhibition have been 
postulated as mechanisms in these cases 
 [4] . Recently, abnormal vascular endothe-
lial growth factor expression has been 
shown in patients with interstitial pneu-
monitis  [5] . We hypothesize that by im-
pairing the alveolar repair mechanism 
through antiangiogenic mechanisms, lung 
injury may be potentiated by bevacizumab 
and may facilitate the development of 
pneumonitis as observed in our patient.
 Here, we report a case of interstitial 
pneumonitis most likely associated with 
the drug bevacizumab. As bevacizumab 
was given in combination with chemo-
therapy, the causative role of bevacizumab 
is not definitely proven. However, since 
the patient’s re-exposure to PLD was with-
out any pulmonary symptoms, pneumoni-
tis was most likely caused or potentiated 
by bevacizumab. Physicians should thus 
be aware of this rare but serious side effect 
when prescribing this drug.
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Table 1. Symptoms, diagnostic procedures and results
At diagnosis At follow-up
Clinical signs and symptoms cough and dyspnea CTC grade III resolved
CT of the chest ground glass opacities in several areas
of the lung (high-resolution CT)
normal
Bronchoscopy with bronchoalveolar lavage total cell count 119 ! 106
lymphocytes 49%
macrophages 48%
neutrophilic granulocytes 1%
eosinophilic granulocytes 2%
no malignant cells
no growth of fungi, bacteriae including acid-fast bacilli
Blood gas analysis on room air at rest pH 7.44
pCO2 35.6 mm Hg
pO2 50.1 mm Hg
alveolo-arterial oxygen gradient 48.4 mm Hg
oxygen saturation 85%
Oxygen saturation by pulse oximetry at rest oxygen saturation 89% oxygen saturation 95%
Lung function tests
Forced vital capacity 3.00 liters (95% predicted) 3.50 liters (111% predicted)
Forced expiratory volume 2.56 liters (95% predicted) 2.74 liters (102% predicted)
Diffusing capacity for carbon monoxide 4.5 mmol/min/kPa (54% predicted) 6.9 mmol/min/kPa
(82% predicted)
CTC = Common terminology criteria for adverse events, version 3.0.
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